Stock listing
TSXV:HEM Hemostemix Inc Stock
Home listing (TSXV) of Hemostemix Inc
Follow Hemostemix Inc into a list and get an email when it puts out news.
Share price · TSXV:HEM
$0.035 CAD 0.000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.035 – $0.035 CADNov 20, 2026
- Volume
- 1,000 sharesNov 20, 2026
- Market cap
- $7.67M CADAt the close on Nov 20, 2026 · price × 219.1M shares outstanding
- 52-week range
- $0.030 – $0.110 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2,430 CADMedian day 7,050 shares · 9 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSXV:HEM · Home | $0.035 CAD | 0.000 (0.0%) | 1,000 | $0.035 | $0.035 | $0.035 | $0.035 | Close on Nov 20, 2026 |
| OTC:HMTXF | $0.027 USD | +0.003 (+11.7%) | 17,140 | $0.027 | $0.027 | $0.027 | $0.024 | Close on Nov 17, 2026 |
| Frankfurt:2VF0 | €0.012 EUR | -0.003 (-17.2%) | — | €0.012 | €0.012 | €0.012 | €0.015 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSXV:HEM · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.035 | 0.000 | 0.0% | $0.035 | $0.035 | $0.035 | 1,000 | |
| $0.035 | 0.000 | 0.0% | $0.035 | $0.035 | $0.030 | 681,800 | |
| $0.035 | 0.000 | 0.0% | $0.030 | $0.035 | $0.030 | 195,700 | |
| $0.035 | -0.015 | -30.0% | $0.045 | $0.045 | $0.030 | 646,300 | |
| $0.050 | 0.000 | 0.0% | $0.045 | $0.050 | $0.045 | 6,000 | |
| $0.050 | 0.000 | 0.0% | $0.050 | $0.050 | $0.050 | 16,500 | |
| $0.050 | 0.000 | 0.0% | $0.050 | $0.050 | $0.050 | 1,000 | |
| $0.050 | 0.000 | 0.0% | $0.045 | $0.050 | $0.045 | 51,000 | |
| $0.050 | 0.000 | 0.0% | $0.050 | $0.050 | $0.050 | 0 | |
| $0.050 | -0.005 | -9.1% | $0.045 | $0.050 | $0.045 | 104,500 | |
| $0.055 | 0.000 | 0.0% | $0.050 | $0.055 | $0.050 | 13,000 | |
| $0.055 | +0.005 | +10.0% | $0.055 | $0.055 | $0.055 | 2,000 | |
| $0.050 | 0.000 | 0.0% | $0.050 | $0.055 | $0.050 | 24,600 | |
| $0.050 | -0.010 | -16.7% | $0.060 | $0.060 | $0.045 | 56,700 | |
| $0.060 | 0.000 | 0.0% | $0.060 | $0.060 | $0.060 | 0 | |
| $0.060 | 0.000 | 0.0% | $0.050 | $0.060 | $0.050 | 95,200 | |
| $0.060 | +0.005 | +9.1% | $0.060 | $0.060 | $0.050 | 73,000 | |
| $0.055 | 0.000 | 0.0% | $0.060 | $0.060 | $0.055 | 6,300 | |
| $0.055 | 0.000 | 0.0% | $0.055 | $0.055 | $0.055 | 0 | |
| $0.055 | 0.000 | 0.0% | $0.060 | $0.060 | $0.055 | 28,300 | |
| $0.055 | -0.005 | -8.3% | $0.055 | $0.055 | $0.055 | 2,000 | |
| $0.060 | +0.005 | +9.1% | $0.060 | $0.060 | $0.060 | 1,000 | |
| $0.055 | 0.000 | 0.0% | $0.065 | $0.065 | $0.050 | 111,300 | |
| $0.055 | -0.005 | -8.3% | $0.055 | $0.055 | $0.055 | 2,100 | |
| $0.060 | 0.000 | 0.0% | $0.055 | $0.060 | $0.055 | 15,000 | |
| $0.060 | 0.000 | 0.0% | $0.055 | $0.065 | $0.055 | 37,150 | |
| $0.060 | 0.000 | 0.0% | $0.055 | $0.060 | $0.055 | 11,000 | |
| $0.060 | -0.015 | -20.0% | $0.060 | $0.060 | $0.055 | 251,900 | |
| $0.075 | 0.000 | 0.0% | $0.075 | $0.075 | $0.075 | 0 | |
| $0.075 | +0.010 | +15.4% | $0.070 | $0.075 | $0.070 | 11,800 | |
| $0.065 | 0.000 | 0.0% | $0.065 | $0.065 | $0.065 | 7,000 | |
| $0.065 | 0.000 | 0.0% | $0.065 | $0.065 | $0.065 | 0 | |
| $0.065 | +0.005 | +8.3% | $0.055 | $0.065 | $0.055 | 21,700 | |
| $0.060 | 0.000 | 0.0% | $0.060 | $0.060 | $0.060 | 0 | |
| $0.060 | 0.000 | 0.0% | $0.060 | $0.060 | $0.060 | 5,000 | |
| $0.060 | 0.000 | 0.0% | $0.060 | $0.060 | $0.060 | 1,100 | |
| $0.060 | 0.000 | 0.0% | $0.060 | $0.060 | $0.060 | 1,000 | |
| $0.060 | +0.005 | +9.1% | $0.060 | $0.060 | $0.060 | 7,100 | |
| $0.055 | -0.010 | -15.4% | $0.055 | $0.055 | $0.055 | 10,000 | |
| $0.065 | 0.000 | 0.0% | $0.060 | $0.065 | $0.060 | 10,000 | |
| $0.065 | -0.005 | -7.1% | $0.070 | $0.070 | $0.060 | 269,500 | |
| $0.070 | 0.000 | 0.0% | $0.070 | $0.070 | $0.070 | 2,600 | |
| $0.070 | 0.000 | 0.0% | $0.070 | $0.070 | $0.070 | 50,000 | |
| $0.070 | -0.005 | -6.7% | $0.070 | $0.070 | $0.070 | 4,000 | |
| $0.075 | +0.005 | +7.1% | $0.075 | $0.075 | $0.075 | 14,100 | |
| $0.070 | 0.000 | 0.0% | $0.070 | $0.070 | $0.070 | 0 | |
| $0.070 | -0.005 | -6.7% | $0.070 | $0.070 | $0.070 | 2,000 | |
| $0.075 | +0.005 | +7.1% | $0.075 | $0.075 | $0.070 | 21,800 | |
| $0.070 | -0.005 | -6.7% | $0.070 | $0.070 | $0.070 | 37,900 | |
| $0.075 | 0.000 | 0.0% | $0.075 | $0.075 | $0.075 | 15,900 | |
| $0.075 | 0.000 | 0.0% | $0.075 | $0.075 | $0.075 | 2,000 | |
| $0.075 | 0.000 | 0.0% | $0.075 | $0.075 | $0.075 | 1,700 | |
| $0.075 | 0.000 | 0.0% | $0.075 | $0.075 | $0.075 | 2,800 | |
| $0.075 | +0.005 | +7.1% | $0.075 | $0.075 | $0.075 | 3,000 | |
| $0.070 | 0.000 | 0.0% | $0.070 | $0.070 | $0.070 | 5,001 | |
| $0.070 | -0.005 | -6.7% | $0.075 | $0.075 | $0.070 | 22,844 | |
| $0.075 | -0.005 | -6.3% | $0.075 | $0.075 | $0.075 | 20,410 | |
| $0.080 | 0.000 | 0.0% | $0.080 | $0.080 | $0.080 | 0 | |
| $0.080 | +0.005 | +6.7% | $0.075 | $0.080 | $0.075 | 59,000 | |
| $0.075 | +0.005 | +7.1% | $0.075 | $0.075 | $0.075 | 1,900 | |
| $0.070 | -0.005 | -6.7% | $0.070 | $0.070 | $0.070 | 1,300 | |
| $0.075 | 0.000 | 0.0% | $0.075 | $0.080 | $0.075 | 113,300 | |
| $0.075 | -0.005 | -6.3% | $0.075 | $0.075 | $0.075 | 5,600 | |
| $0.080 | 0.000 | 0.0% | $0.080 | $0.080 | $0.080 | 0 |
Splits
1 split · TSXV:HEM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- TSXV:HEM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TSXV
- Currency
- CAD
What changed lately
Latest news release · Nov 19, 2026
Hemostemix to Highlight Commercial Phase I Longevity Treatment at Small Cap Growth Investor Conference
Latest deck · Nov 4, 2026
Investor Presentation (2026)
Investor deck · 17 slides
Latest news
Small Cap Growth Virtual Investor Conference Presentations Now Available On Demand
Nov 20, 2026
Closed $0.035 (0.0%) on Nov 20, 2026
Issued by another party
Hemostemix to Highlight Commercial Phase I Longevity Treatment at Small Cap Growth Investor Conference
Nov 19, 2026
Closed $0.035 (0.0%) on Nov 20, 2026
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Oct 7, 2026
Closed $0.065 (0.0%) on Oct 7, 2026
Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit
Sep 28, 2026
Closed $0.06 (+9.1%) on Sep 28, 2026
Hemostemix Non Brokered Private Placement
Sep 23, 2026
Closed $0.065 (0.0%) on Sep 24, 2026
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Aug 20, 2026
Closed $0.08 (0.0%) on Aug 20, 2026
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Aug 12, 2026
Closed $0.07 (+7.7%) on Aug 12, 2026
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
Jul 30, 2026
Closed $0.06 (0.0%) on Jul 31, 2026
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Jul 28, 2026
Closed $0.07 (+16.7%) on Jul 28, 2026
Hemostemix grants 6,280,000 options
Jul 22, 2026
Closed $0.06 (0.0%) on Jul 23, 2026
Hemostemix Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 32 in the last 12 months · 217 in all · newest Nov 20, 2026 · oldest 2013
- Decks
- 14 decks · latest Nov 4, 2026
Where Hemostemix Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSXV:HEM · Home listing · This page | TSXV | Canada | CAD |
| OTC:HMTXF | OTC | United States | USD |
| LS Exchange:A2QQGU | LS Exchange | Germany | EUR |
| Cboe Canada:HEM | Cboe Canada | Canada | CAD |
| Frankfurt:2VF0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2QQGU | Lang & Schwarz | Germany | EUR |
| Stuttgart:2VF0 | Stuttgart | Germany | EUR |
| Tradegate:2VF0 | Tradegate | Germany | EUR |
Valuation
Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $11.03M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P/TSX Composite
- 0.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Hemostemix Inc · TSXV:HEM | US$5.35M | US$7.69M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| Oncotelic Therapeutics Inc · OTC:OTLC | US$5.58M | US$5.52M | 0.0× | n/a | n/a | 0.0× | n/a | 0.0× | 0.07 |
| Theriva Biologics, Inc. · AMEX:TOVX | US$5.51M | US$461,120 | n/a | n/a | n/a | 0.5× | n/a | 0.3× | 2.65 |
| Curative Biotechnology Inc · OTC:CUBT | US$5.34M | US$6.55M | n/a | n/a | n/a | n/a | n/a | n/a | 1.27 |
| Abpro Holdings, Inc. · OTC:ABPO | US$5.31M | US$1.07M | 2.6× | n/a | n/a | n/a | n/a | n/a | -0.79 |
| CNS Pharmaceuticals, Inc. · NASDAQ:CNSP | US$5.25M | −US$11.96M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.74 |
| Soligenix, Inc. · NASDAQ:SNGX | US$5.14M | −US$3.61M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | 1.76 |
| Rakovina Therapeutics Inc · TSXV:RKV | US$5.10M | US$7.20M | n/a | n/a | n/a | n/a | n/a | n/a | -0.43 |
| StimCell Energetics Inc. · OTC:STME | US$5.10M | US$5.09M | n/a | n/a | n/a | n/a | n/a | n/a | 0.99 |
| Longeveron Inc. · NASDAQ:LGVN | US$5.05M | −US$1.78M | n/a | −1.5× | n/a | 1.1× | n/a | 0.1× | 1.55 |
| Oncodesign Precision Medicine S.A. · EURONEXT:ALOPM | US$5.04M | US$8.61M | 0.8× | 30.0× | 0.9× | 1.2× | n/a | 1.6× | n/a |
| Median of the others | US$5.20M | US$3.08M | 0.8× | 14.3× | 0.9× | 0.7× | 0.1× | 0.99 |
Team and board
Officers
| Officer | Role |
|---|---|
| Thomas A. Smeenk | President & CEO. Co-Founder |
| Fraser Henderson | Chief Medical Officer |
| Shaune Harding | Director of Patient Care & Clinical Operations |
Board
| Director | Role |
|---|---|
| Peter Lacey | Chairman of the Board |
| Desirée Cox | Director |
| Loran Swanberg | Director |
| Ronnie Hershman | Director |
Events
- Next results
- Nov 27, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | May 29, 2023 · After close | −3.9% |
| Q3 2022 | Nov 29, 2022 · After close | +6.7% |
| Q2 2022 | Aug 30, 2022 · Before open | −38.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2026) | Investor deck | 17 slides | Nov 4, 2026 |
| Investor Presentation (2026) | Investor deck | 23 slides | 2026 |
| Investor Presentation (2025) | Investor deck | 22 slides | Nov 3, 2025 |
| Investor Presentation (July 2023) | Investor deck | 23 slides | Jul 5, 2023 |
| Investor Presentation (April 2023) | Investor deck | 24 slides | April 2023 |
| Investor Presentation (November 2022) | Investor deck | 22 slides | November 2022 |
| Investor Presentation (March 2022) | Investor deck | 18 slides | Mar 29, 2022 |
| Non-Deal Roadshow (February 2022) | Roadshow | 14 slides | February 2022 |
| Investor Presentation (January 2021) | Investor deck | 22 slides | Jan 25, 2021 |
| Investor Presentation (April 2019) | Investor deck | 20 slides | Apr 1, 2019 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2018) | Investor deck | 21 slides | Jul 26, 2018 |
| Investor Presentation (November 2015) | Investor deck | 21 slides | Nov 12, 2015 |
| Investor Presentation (September 2015) | Investor deck | 21 slides | September 2015 |
| Investor Presentation (July 2015) | Investor deck | 19 slides | July 2015 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Tranche closed: C$380,500 in the latest tranche · C$0.05 a unit · ½ warrant at C$0.12 for 24 months Use of proceeds: ACP-01 manufacturing, clinical-program preparation, regulatory submissions, physician education and general working capital | Oct 7, 2026 | |
| Private placement of units Tranche closed: C$360,000 raised · C$0.05 a unit · ½ warrant at C$0.12 for 24 months Insiders: Certain directors of the Company participated, directly and indirectly, in the Offering Use of proceeds: Sales, marketing, patient acquisition and commercialization; ACP-01 production; Bahamas regulatory fees; working capital | Jun 26, 2026 | |
| Private placement of units Announced: up to C$1M · C$0.05 a unit · ½ warrant at C$0.12 for 24 months Insiders: Certain directors of the Company may participate in the private placement, a related party transaction under MI 61-101 Use of proceeds: Sales, marketing, patient acquisition, physician education, commercialization, ACP-01 production, Bahamas regulatory fees and working capital | Jun 17, 2026 | US$712,555 |
| Private placement of common shares Closed: C$480,000 raised · C$0.12 a share Use of proceeds: General working capital, including regulatory, clinical and commercialization work on ACP-01 (VesCell) | Dec 31, 2025 | US$350,212 |
| Private placement of units Closed: C$518,440 raised · C$0.11 a unit · 1 warrant at C$0.15 for 24 months Buyers: Director of the Company (participating in the Offering) Insiders: Certain directors participated directly and indirectly Use of proceeds: General working capital and ongoing operations, including marketing and sales of VesCell | Dec 2, 2025 | |
| Private placement of common shares Closed: C$280,594 raised · C$0.125 a share Insiders: The investor is arm's length and not a Related Party to the Company. Use of proceeds: General working capital, ongoing operating expenses and business development. | Nov 18, 2025 | US$200,467 |
| Therapy Convertible Debenture Tranche closed: US$1.14M raised Use of proceeds: General working capital, corporate overhead and research and development activities | Aug 20, 2025 | |
| Private placement of units Closed: C$2.97M raised · C$0.1 a unit · 1 warrant at C$0.15 for 24 months Buyers: Peter Lacey (subscribed for $1,500,000); Loran Swanberg (subscribed for $100,000); Mr. Lacey (subscribed to 15,000,000 Units; now owns 24,316,937 Common Shares (13.40% non-diluted)) Insiders: Directors Peter Lacey and Loran Swanberg directly and indirectly participated; related party transaction under MI 61-101 Use of proceeds: Repay CD#1 in full at a 50% discount ($1,250,000) and general working capital, including marketing and sales of VesCell | Jul 31, 2025 | US$2.18M |
| Private placement of common shares Closed: C$469,366 raised · C$0.12 a share Insiders: The investor is arm's length to the Company and is not a Related Party Use of proceeds: General working capital, operational expenses and business development | Jul 4, 2025 | US$345,046 |
| Private placement of common shares Closed: US$336,500 raised · C$0.295 a share Buyers: CytoImmune (USD $336,500 for 1,634,466 Common Shares); CytoImmune Therapeutics LLC (1,634,466 Common Shares at CAD $0.295 each) Use of proceeds: General working capital, including business development activities | May 12, 2025 |
All 11 raises
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Closed: C$2.73M raised · C$0.05 a unit · 1 warrant at C$0.12 for 24 months Insiders: Certain directors of the Company participated in the Offering, a related party transaction under MI 61-101 Use of proceeds: Advance stem cell therapeutics platform, initiate sales and process initial ACP batches, pay fees, and general working capital | Dec 3, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 223 | 495 | 1.10K | 2.45K | 1.69K | 0 | 0 | |||
| Gross profit | -223 | -495 | -1.10K | -2.45K | -1.69K | 0 | 0 | |||
| Research and development | 2.49M | 2.97K | 384.9K | 622.7K | 179.9K | 650.0K | 2.35M | 2.26M | 60.3K | 828.6K |
| Selling, general and administrative | 2.56M | 1.89M | 1.33M | 3.50M | 5.98M | 6.81M | 2.34M | 4.16M | 2.75M | 2.31M |
| Operating income | -5.63M | -1.98M | -2.16M | -4.58M | -6.67M | -7.47M | -4.70M | -6.42M | -2.81M | -3.71M |
| Depreciation and amortization | 46 | 100 | 223 | 495 | 1.10K | 2.45K | 1.69K | 1.69K | 745.6K | 38.6K |
| EBITDA | -5.63M | -1.98M | -2.16M | -4.58M | -6.67M | -7.47M | -4.69M | -6.42M | -2.06M | -3.67M |
| Interest expense | 453.2K | 615.2K | 550.1K | 350.3K | 10.5K | 106.0K | 105.0K | 0 | 1.14M | 2.27K |
| Income before tax | -4.71M | -2.62M | -2.50M | -4.75M | -6.54M | -7.77M | -4.87M | -6.18M | -3.51M | -3.79M |
| Income tax | -3 | 486.9K | -255.8K | 106.0K | 105.0K | 6.22K | -60.2K | -10.3K | ||
| Net income | -4.71M | -2.62M | -2.50M | -5.24M | -6.29M | -7.77M | -4.87M | -6.19M | -3.93M | -3.78M |
| Earnings per share, basic | -0.02 | -0.02 | -0.03 | -0.07 | -0.11 | -0.24 | -0.32 | -0.41 | -0.56 | -1.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 682.1K | 705.7K | 155.4K | 135.7K | 219.4K | 258.0K | 24.1K | 1.47M | 3.96M | 34.8K |
| Short-term investments | 59.6K | 0 | 1.25M | |||||||
| Receivables | 25.1K | 138.9K | 342.7K | 2.06M | 75.8K | 191.2K | 89.1K | 90.4K | ||
| Inventory | -343 | -45.5K | -13.3K | -88.2K | -62.0K | -74.4K | ||||
| Current assets | 846.9K | 991.8K | 313.6K | 464.9K | 562.1K | 2.32M | 99.8K | 1.66M | 5.30M | 125.3K |
| Property, plant and equipment | 406 | 2.00K | 4.45K | 101.8K | ||||||
| Goodwill | 1 | 1 | ||||||||
| Total assets | 846.9K | 991.9K | 313.8K | 465.3K | 563.0K | 2.32M | 104.3K | 1.66M | 5.30M | 227.1K |
| Accounts payable | 1.73M | 2.77M | 2.88M | 2.40K | 4.37M | 3.25M | 2.09M | 1.17M | 412.0K | 953.4K |
| Current liabilities | 1.73M | 2.77M | 2.88M | 2.62M | 4.37M | 3.42M | 4.15M | 1.17M | 464.8K | 3.38M |
| Long-term debt | 3.60M | 4.94M | 4.32M | 4.13M | 1.48M | 312.7K | ||||
| Total debt | 4.32M | 4.13M | 1.48M | 175.0K | 2.06M | 1.39M | ||||
| Total liabilities | 5.82M | 8.20M | 7.68M | 7.23M | 5.85M | 3.42M | 4.15M | 1.17M | 464.8K | 3.69M |
| Shareholders' equity | -4.97M | -7.20M | -7.37M | -6.77M | -5.28M | -1.10M | -4.05M | 487.8K | 4.84M | -3.46M |
| Shares outstanding | 195.3M | 140.6M | 82.5M | 70.0M | 57.4M | 32.2M | 15.0M | 14.9M | 6.98M | 3.37M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -4.53M | -1.90M | -1.50M | -6.10M | -3.48M | -5.98M | -3.40M | -2.69M | -3.21M | -2.69M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | -6.14K | -6.14K | -6.14K | -1.53K |
| Free cash flow | -4.53M | -1.90M | -1.50M | -6.10M | -3.48M | -5.98M | -3.41M | -2.69M | -3.21M | -2.69M |
| Cash from investing | -6.14K | -6.14K | -6.14K | -1.53K | ||||||
| Cash from financing | 4.66M | 2.45M | 1.52M | 6.02M | 3.27M | 6.21M | 1.96M | 201.6K | 7.14M | 2.22M |
| Share buybacks | 5.89M | 76.0K | ||||||||
| Change in cash | -23.6K | 550.3K | 19.7K | -83.7K | -38.5K | 233.9K | -1.45M | -2.49M | 3.92M | -471.7K |
Cap table
Built by 6ix from Hemostemix Inc’s releases · as of Oct 7, 2026
- Common shares
- 219,051,432
- Fully diluted
- 295,732,757
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 219,051,432 | Oct 7, 2026 |
| Warrants | 70,401,325 | Jul 30, 2026 |
| Options and RSUs | 6,280,000 | Jul 22, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · C$0.12 · expire about Jul 2028 |
| Warrants · C$0.12 · expire about Jun 2028 |
| Warrants · C$0.15 · expire about Nov 2027 |
| Warrants · C$0.15 · expire about Jul 2027 |
| Warrants · C$0.12 · expire about Nov 2026 |
| Broker warrants · C$0.06 · expiry not stated |
| Broker warrants · C$0.06 · expiry not stated |
| Broker warrants · C$0.06 · expiry not stated |
| Stock options · C$0.06 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Oct 7, 2026 | 219,051,432 |
| Jul 30, 2026 | 211,441,432 |
| Jun 30, 2026 | 204,996,432 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Desiree Cox | Director · Since May 25, 2026 |
| Fraser Henderson | Chief Medical Officer · Since at least Jan 16, 2026 |
| John M. Viglotti | SVP Corporate Services · Sep 18, 2025 – Nov 4, 2026 · Past |
| Loran Swanberg | Director · Since at least Jul 31, 2025 |
| Peter Lacey | Chairman of the Board · Since at least Mar 9, 2026 |
| Ronnie Hershman | Director · Since at least Nov 4, 2026 |
| Shaune Harding | Director of Patient Care & Clinical Operations · Since at least Dec 4, 2025 |
| Thomas Smeenk | President & CEO. Co-Founder · Since at least Oct 7, 2026 |
Log in to ask 6ix AI your own questions about Hemostemix Inc.